You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 10,329,260


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,329,260 protect, and when does it expire?

Patent 10,329,260 protects ORLADEYO and is included in one NDA.

This patent has fifty-nine patent family members in twenty-eight countries.

Summary for Patent: 10,329,260
Title:Human plasma kallikrein inhibitors
Abstract: Disclosed are compounds of formula I ##STR00001## as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Inventor(s): Kotian; Pravin L. (Hoover, AL), Babu; Yarlagadda S. (Birmingham, AL), Wu; Minwan (Vestavia Hills, AL), Chintareddy; Venkat R. (Vestavia Hills, AL), Kumar; V. Satish (Birmingham, AL), Zhang; Weihe (Vestavia, AL)
Assignee: BioCryst Pharmaceuticals, Inc. (Durham, NC)
Application Number:15/977,129
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 10,329,260

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biocryst ORLADEYO berotralstat hydrochloride CAPSULE;ORAL 214094-001 Dec 3, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Biocryst ORLADEYO berotralstat hydrochloride CAPSULE;ORAL 214094-002 Dec 3, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,329,260

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3113772 ⤷  Sign Up 301142 Netherlands ⤷  Sign Up
European Patent Office 3113772 ⤷  Sign Up CA 2021 00040 Denmark ⤷  Sign Up
European Patent Office 3113772 ⤷  Sign Up PA2021524 Lithuania ⤷  Sign Up
European Patent Office 3113772 ⤷  Sign Up LUC00233 Luxembourg ⤷  Sign Up
European Patent Office 3113772 ⤷  Sign Up 2021C/544 Belgium ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.